Evolus Inc
EOLS · NASDAQ
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.
Market Data
Price
$5.39
+0.21 (+4.05%)
Market Cap$337M
P/E Ratio—
EPS$—
52W High$12.28
52W Low$3.86
Beta1.28
Data from Finnhub · Updated May 1, 2026